Intelligent Bio Solutions holder reports 5.91% stake
Intelligent Bio Solutions Inc. received an amended passive ownership report from Armistice Capital, LLC and Steven Boyd.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. received an amended passive ownership report from Armistice Capital, LLC and Steven Boyd. The reporting persons disclose beneficial ownership of 141,397 shares of common stock, representing 5.91% of the class. All 141,397 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive authority. Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and may be deemed to beneficially own these securities. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own the same shares. The Master Fund has the right to receive dividends or sale proceeds on the reported securities.
Key Figures
Key Terms
beneficially own financial
Investment Management Agreement financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in INBS does Armistice Capital report on this Schedule 13G/A?
Who are the reporting persons in the INBS Schedule 13G/A filing?
What is the role of Armistice Capital Master Fund Ltd. in the INBS position?
Why is Steven Boyd included as a reporting person for INBS?
AI-generated analysis. How Rhea-AI works. Not financial advice.